Bellicum planning changes to end clinical hold
Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA has outlined criteria required to lift the agency's clinical hold on U.S. trials of adjunct T cell therapy BPX-501. The treatment, which consists of genetically modified donor cells and contains the company's CaspaCIDe safety switch, is in Phase I and Phase I/II testing to improve allogeneic hematopoietic stem cell transplant (HSCT) outcomes in patients with hematological cancers or inherited blood disorders who lack a matched donor.
In January, FDA placed the hold after it said three reported cases of encephalopathy were possibly related to the candidate (see BioCentury, Feb. 2)...
BCIQ Company Profiles
BCIQ Target Profiles